ABIVAX and the Center for Genetic Engineering and Biotechnology (CIGB) announced that Cuban regulatory authorities have granted their first marketing authorization application for ABX203 (HeberNasvac), a first-in-class vaccine to treat chronic hepatitis B (CHB). “The immune responses observed in CHB patients receiving ABX203, during clinical testing, clearly show that the therapeutic vaccine is able to help … Continue reading New Chronic Hepatitis B Treatment Available in Cuba